Kezar Life Sciences, INC. (KZR) — SEC Filings

Overview

Kezar Life Sciences, INC. (KZR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a SC14D9C filed on Mar 30, 2026: Kezar Life Sciences, Inc. filed a SC14D9C form on March 30, 2026, related to a third-party tender offer. The filing details the company's address and business information, indicating it is involved in the pharmaceutical preparations industry.

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 3 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Kezar Life Sciences, INC. is neutral.

Filing Type Overview

Kezar Life Sciences, INC. (KZR) has filed 1 SC14D9C, 18 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D, 8 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

• Kezar Life Sciences Files SC14D9C for Tender Offer — SC14D9C · Mar 30, 2026 Risk: medium
  Kezar Life Sciences, Inc. filed a SC14D9C form on March 30, 2026, related to a third-party tender offer. The filing details the company's address and business i
• Kezar Life Sciences Files 8-K for Material Agreement — 8-K · Mar 30, 2026 Risk: medium
  Kezar Life Sciences, Inc. filed an 8-K on March 30, 2026, to report the entry into a material definitive agreement. The filing also includes Regulation FD discl
• Kezar Narrows Q3 Loss Amid Strategic Review, 70% Workforce Cut — 10-Q · Nov 12, 2025 Risk: high
  Kezar Life Sciences, Inc. (KZR) reported a net loss of $11.2 million for the three months ended September 30, 2025, a significant improvement from the $20.3 mil
• Kezar Life Sciences Reports Exit/Disposal Costs — 8-K · Nov 7, 2025 Risk: medium
  Kezar Life Sciences, Inc. filed an 8-K on November 7, 2025, reporting costs associated with exit or disposal activities as of November 6, 2025. The filing does
• Kezar Life Sciences Terminates Material Agreement — 8-K · Oct 22, 2025 Risk: medium
  Kezar Life Sciences, Inc. announced on October 20, 2025, the termination of a material definitive agreement. The filing does not specify the counterparty or the
• Kezar Life Sciences Files 8-K with Key Updates — 8-K · Oct 16, 2025 Risk: medium
  Kezar Life Sciences, Inc. filed an 8-K on October 16, 2025, reporting on several key events. These include entering into a material definitive agreement, update
• Kezar Narrows Q2 Loss on Reduced R&D Spending — 10-Q · Aug 13, 2025 Risk: high
  Kezar Life Sciences, Inc. (KZR) reported a net loss of $13.7 million for the three months ended June 30, 2025, a significant improvement from the $21.5 million
• Kezar Life Sciences Files 8-K on Shareholder Matters — 8-K · Jun 23, 2025 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders as of June 17, 2025. The filing details th
• Kezar Life Sciences Q1 2025 Financial Update — 10-Q · May 13, 2025 Risk: low
  Kezar Life Sciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company's financial statements show changes in common stock, addi
• Kezar Life Sciences Executive Compensation Details — DEF 14A · Apr 25, 2025 Risk: low
  Kezar Life Sciences, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing include
• Kezar Life Sciences Files 8-K on Officer/Director Changes — 8-K · Apr 1, 2025 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on April 1, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment
• Kezar Life Sciences Files 2024 10-K — 10-K · Mar 25, 2025 Risk: medium
  Kezar Life Sciences, Inc. filed its 2024 10-K on March 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company,
• Kezar Life Sciences Files 8-K — 8-K · Feb 27, 2025 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on February 27, 2025, reporting other events and financial statements. The filing details the company's principal executi
• Kezar Life Sciences Files 8-K on Financials — 8-K · Jan 10, 2025 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on January 10, 2025, reporting on its Results of Operations and Financial Condition. The filing details the company's sta
• Kezar Life Sciences Files 8-K on Material Agreements — 8-K · Dec 3, 2024 Risk: medium
  Kezar Life Sciences, Inc. filed an 8-K on December 3, 2024, reporting a material definitive agreement and material modifications to the rights of security holde
• Kezar Life Sciences Faces Nasdaq Delisting Warning — 8-K · Nov 14, 2024 Risk: medium
  Kezar Life Sciences, Inc. announced on November 13, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. T
• Kezar Life Sciences Q3 2024 Update — 10-Q · Nov 12, 2024 Risk: medium
  Kezar Life Sciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations, in
• Kezar Life Sciences Files 8-K with Corporate Updates — 8-K · Oct 28, 2024 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on October 28, 2024, reporting material modifications to the rights of security holders and amendments to its articles of
• Kezar Life Sciences Files 8-K — 8-K · Oct 17, 2024 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on October 17, 2024, reporting on several items including entry into a material definitive agreement, results of operatio
• Kezar Life Sciences Files 8-K — 8-K · Oct 10, 2024 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on October 10, 2024, to report other events and financial statements. The filing does not contain specific details about
• Tang Capital Discloses 10.7% Stake in Kezar Life Sciences — SC 13D · Oct 8, 2024 Risk: medium
  On October 8, 2024, Tang Capital Management LLC, along with associated entities and Kevin Tang, filed a Schedule 13D indicating they collectively beneficially o
• Kezar Life Sciences Files 8-K — 8-K · Oct 4, 2024 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on October 4, 2024, reporting other events and financial statements. The filing does not contain specific details about t
• Kezar Life Sciences Files 8-K — 8-K · Sep 30, 2024 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing does not contain specific financial fi
• Kezar Life Sciences Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Kezar Life Sciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, includi
• SC 13G/A Filing — SC 13G/A · Jul 8, 2024
• Kezar Life Sciences Reports on Shareholder Vote Matters — 8-K · Jun 21, 2024 Risk: low
  Kezar Life Sciences, Inc. filed an 8-K on June 21, 2024, reporting on matters submitted to a vote of security holders on June 18, 2024. The filing details the c
• Kezar Life Sciences Faces Delisting Concerns — 8-K · Jun 4, 2024 Risk: high
  Kezar Life Sciences, Inc. filed an 8-K on May 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in
• Kezar Life Sciences Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Kezar Life Sciences, Inc. (KZR) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Kezar Life Sciences, Inc. filed a 10-Q report for the period ending
• Kezar Life Sciences Files DEF 14A with Executive Compensation Details — DEF 14A · Apr 26, 2024 Risk: low
  Kezar Life Sciences, Inc. (KZR) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Filing is a DEF 14A (Definitive Proxy Statement) for Kezar Lif
• Kezar Life Sciences Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024 Risk: medium
  Kezar Life Sciences, Inc. (KZR) filed a Annual Report (10-K) with the SEC on March 14, 2024. Kezar Life Sciences, Inc. filed its 10-K report for the fiscal year
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Amends Kezar Life Sciences Stake as of Dec 31, 2023 — SC 13G/A · Jan 29, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership of Kezar Life Sciences, Inc. common stock as of December 31, 2023. This a
• State Street Corp. Updates Passive Stake in Kezar Life Sciences — SC 13G/A · Jan 23, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Kezar Life Sciences Inc. com
• Millennium Management Amends Kezar Life Sciences Stake — SC 13G/A · Jan 22, 2024
  Millennium Management LLC, a hedge fund led by Israel A. Englander, filed an amended SC 13G/A on January 22, 2024, disclosing its ownership of Kezar Life Scienc
• Kezar Life Sciences Files 8-K on Financial Condition — 8-K · Jan 8, 2024
  Kezar Life Sciences, Inc. filed an 8-K on January 8, 2024, under Item 2.02, 'Results of Operations and Financial Condition.' This filing indicates that the comp

Risk Profile

Risk Assessment: Of KZR's 29 recent filings, 3 were flagged as high-risk, 13 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Kezar Life Sciences, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: N/A
• Net Income: -$11.2M
• EPS: -$1.53
• Debt-to-Equity: 0.18
• Cash Position: $38.9M
• Operating Margin: N/A
• Total Assets: $97.7M
• Total Debt: $6.6M

Key Executives

• Dr. Krick
• Mr. Fowler
• Kevin Tang
• Dr. Henig
• Mr. Belsky

Industry Context

Kezar Life Sciences operates in the highly competitive biotechnology sector, characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. The industry is driven by innovation in drug discovery and development, with companies often relying on external funding and strategic partnerships to advance their pipelines. Recent trends include increased focus on cost management and pipeline prioritization amidst evolving market dynamics and investor sentiment towards early-stage biotechs.

Top Tags

8-K (5) · corporate-governance (4) · 10-Q (4) · material-agreement (3) · Biotechnology (3) · financial-condition (3) · financials (3) · biotech (3) · Kezar Life Sciences (3) · institutional-ownership (3)

Key Numbers

• Net Loss (Q3 2025): $11.2M — Decreased from $20.3M in Q3 2024, indicating reduced burn.
• Net Loss (9M 2025): $41.5M — Decreased from $63.5M in 9M 2024, reflecting cost-cutting.
• R&D Expenses (Q3 2025): $6.9M — Significant drop from $16.2M in Q3 2024, a key driver of reduced loss.
• R&D Expenses (9M 2025): $28.7M — Substantial decrease from $49.7M in 9M 2024, indicating a pivot from active development.
• Cash & Cash Equivalents: $38.9M — As of Sept 30, 2025, down from $41.7M at Dec 31, 2024, reflecting ongoing cash burn.
• Marketable Securities: $51.3M — As of Sept 30, 2025, significantly down from $90.5M at Dec 31, 2024, used to fund operations.
• Accumulated Deficit: $476.0M — As of Sept 30, 2025, highlighting substantial historical losses and no product sales.
• Workforce Reduction: 70% — Implemented on Nov 6, 2025, indicating a severe operational restructuring and potential wind-down.
• Estimated Severance Costs: $6.0M — Expected in Q4 2025 due to workforce reduction, impacting near-term cash.
• Net Loss (Q2 2025): $13.7M — Decreased from $21.5M in Q2 2024, showing improved financial performance.
• Research and Development Expenses (Q2 2025): $9.6M — Significantly reduced from $16.3M in Q2 2024, indicating cost control.
• Net Loss (Six Months Ended June 30, 2025): $30.3M — Lower than $43.2M for the same period in 2024, reflecting overall loss reduction.
• Cash, Cash Equivalents, and Marketable Securities: $100.9M — Total current liquidity as of June 30, 2025, down from $132.2M at Dec 31, 2024.
• Liquidity Runway: 12 months — Management's estimate for funding cash requirements with existing capital.
• Shares Outstanding: 7,315,931 — As of June 30, 2025, reflecting a slight increase from 7,303,629 at Dec 31, 2024.

Frequently Asked Questions